6IRA Stock Chart & Stats
€0.18
-€0.01(-1.25%)
At close: 4:00 PM EST
€0.18
-€0.01(-1.25%)
Day’s Range― - ―
52-Week Range€0.10 - €0.28
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€21.92M
Enterprise Value€99.29
Total Cash (Recent Filing)€50.79M
Total Debt (Recent Filing)€27.08M
Price to Earnings (P/E)―
Beta0.05
Next Earnings
Aug 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.04
Shares Outstanding146,382,140
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.48
Price to Book (P/B)4.30
Price to Sales (P/S)2.30
P/FCF Ratio-2.39
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.23
Revenue Forecast (FY)€9.23M
Bulls Say, Bears Say
Bulls Say
Revenue ReboundA durable, strong TTM revenue rebound of +60.9% indicates improving commercial or licensing traction and program milestones. For a development-stage biotech, sustained revenue growth can reduce reliance on financing, improve partner bargaining leverage, and signal advancing pipeline de‑risking over the next 2–6 months.
Moderate LeverageDebt/equity near 0.68 and improvement versus the prior year reflect partial balance‑sheet repair, lowering near‑term solvency risk. Moderate leverage improves flexibility to fund R&D or negotiate partnerships without immediate refinancing pressure, supporting operational continuity in the medium term.
Focused CNS R&D PipelineA clear, specialized therapeutic focus on Parkinson’s and CNS disorders creates long‑term competitive differentiation and scientific expertise. This concentration enhances potential for strategic collaborations or asset licensing, and aligns the company with enduring unmet medical needs and partner interest in neurology.
Bears Say
Persistent Negative MarginsSustained negative gross profit and a ~-72% net margin show core operations are not cash generative; for a development biotech this signals that R&D costs far outstrip revenues. Persisting losses erode resilience, constrain reinvestment, and heighten dependency on external capital to progress clinical programs.
High Cash BurnMaterial TTM operating and free cash flow deficits (~-90M) represent a stable, significant cash outflow profile for a small company. This burn rate creates structural funding risk, increases likelihood of dilutive financing or debt, and can impede multi‑program advancement unless addressed through partnerships or capital raises.
Eroding Equity & Negative ROEShrinking equity and persistently negative returns on equity reflect cumulative losses that weaken the capital base. This reduces strategic optionality, raises cost of capital, and can limit the company’s ability to secure non‑dilutive funding or favorable partnership terms over the medium term.
IRLAB Therapeutics AB Class A News
6IRA FAQ
What was IRLAB Therapeutics AB Class A’s price range in the past 12 months?
IRLAB Therapeutics AB Class A lowest stock price was €0.10 and its highest was €0.28 in the past 12 months.
What is IRLAB Therapeutics AB Class A’s market cap?
IRLAB Therapeutics AB Class A’s market cap is €21.92M.
When is IRLAB Therapeutics AB Class A’s upcoming earnings report date?
IRLAB Therapeutics AB Class A’s upcoming earnings report date is Aug 26, 2026 which is in 9 days.
How were IRLAB Therapeutics AB Class A’s earnings last quarter?
IRLAB Therapeutics AB Class A released its earnings results on May 06, 2026. The company reported €0.01 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is IRLAB Therapeutics AB Class A overvalued?
According to Wall Street analysts IRLAB Therapeutics AB Class A’s price is currently Overvalued.
Does IRLAB Therapeutics AB Class A pay dividends?
IRLAB Therapeutics AB Class A does not currently pay dividends.
What is IRLAB Therapeutics AB Class A’s EPS estimate?
IRLAB Therapeutics AB Class A’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does IRLAB Therapeutics AB Class A have?
IRLAB Therapeutics AB Class A has 146,382,140 shares outstanding.
What happened to IRLAB Therapeutics AB Class A’s price movement after its last earnings report?
IRLAB Therapeutics AB Class A reported an EPS of €0.01 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -14.634%.
Which hedge fund is a major shareholder of IRLAB Therapeutics AB Class A?
Currently, no hedge funds are holding shares in DE:6IRA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
IRLAB Therapeutics AB Class A
IRLAB Therapeutics AB (publ) is a pharmaceutical company committed to developing treatments for Parkinson's disease. Its clinical pipeline features Mesdopetam, currently progressing through phase IIb/III studies to address dyskinesia, and Pirepemat, which is undergoing phase IIb clinical trials for the management of postural dysfunction. In the preclinical phase, IRLAB is advancing research programs like IRL942 and 1009, aimed at neurodegenerative conditions and the aging process, as well as IRL757, designed to alleviate apathy in various neurological disorders. Additionally, the company is conducting a research project, P003, focused on creating new therapies for individuals with a recent Parkinson's disease diagnosis. IRLAB Therapeutics AB (publ) was founded in 2013 and has its headquarters in Gothenburg, Sweden.
Technical Analysis
Isofol Medical AB
―
Xintela AB
―
Elicera Therapeutics AB
―
Active Biotech AB
―
Initiator Pharma A/S
―